Sign up for email alertsSign up today
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the clinical development of products to address unmet medical needs for the treatment of cancer. Our antibody HuMab-5B1, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in over 90% of pancreatic cancer (PDAC) and in other diseases including small cell lung, colon and other GI cancers.
The Company's lead therapeutic program, MVT-1075, is a new human antibody-based radioimmunotherapy (RIT) product, currently being evaluated in a Phase 1 clinical study for the treatment of pancreatic, colon and lung cancer. Patient enrollment and dosing in the initial cohort was recently completed and interim data is expected in Q1 2018.
MVT-5873, the Company's therapeutic agent which utilizes the HuMab-5B1 antibody, is currently in Phase 1 development for patients with pancreatic cancer and other CA19-9 positive tumors. The Company completed its monotherapy Phase 1a cohort and recently completed enrollment and initial patient dosing in an expanded cohort of the Phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in newly diagnosed treatment naive patients.
MVT-2163, the Company's immunoPET imaging diagnostic product which utilizes the HuMab-5B1 antibody coupled with a PET imaging agent, is in Phase 1 development for the diagnosis and treatment assessment of pancreatic cancer and CA19-9 malignancies including lung and GI cancers. MVT-5873 and MVT-2163 are being developed with in collaboration with Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon Research Institute, HonorHealth and Imaging Endpoints, and have demonstrated early safety, specificity for the target and a potential efficacy signal.